C4 Therapeutics (CCCC) Fundamentals 2026 — Revenue Analysis | SniperIQ
C4 Therapeutics (CCCC) is a US-listed Healthcare company in Biotechnology with a market capitalization of
C4 Therapeutics (CCCC) has a market capitalization of approximately
C4 Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
C4 Therapeutics runs a net profit margin of -297.8%, a gross margin of 94.8%, and an operating margin of -326.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
C4 Therapeutics reported revenue of
C4 Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
C4 Therapeutics carries a debt-to-equity ratio of 0.25x and a current ratio of 9.00x, with a market beta of 2.91. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For C4 Therapeutics (CCCC) the key facts are: market cap
Get C4 Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.